The human genome project has identified, besides ovarian relaxin (RLN), six other relaxin-like molecules (RLN3, H1-RLN, INSL3-6), most of which appear to be expressed in the testis and/or male reproductive system, together with four different G-proteincoupled receptors responsive to one or other of these peptides. Earlier work on relaxin in the male assumed the simplistic hypothesis of only a single relaxin-like entity. This review systematically examines the expression and physiology of relaxin-like molecules in the male reproductive system in order to reappraise the importance of this hormone system for male reproductive function. Although there are important species differences, only INSL3 and INSL6 appear to be generally expressed at a moderately high level within the testis, whereas ovarian RLN is consistently a major secretory product of the prostate epithelium. However, all members of this relaxin-like family appear to be expressed also at a low level in different organs of the male reproductive system, suggesting possible autocrine/paracrine effects. The four receptors (RXFP1-4) for these peptides are also expressed to differing levels in both somatic and seminiferous compartments of the testis and in the prostate, supporting relevant functions for most members of this interesting peptide family. Recent studies of relaxin family peptides in prostate pathology highlight their functional importance in the clinical context as potential causative, diagnostic and therapeutic agents and warrant more specific and detailed studies of their roles also in regard to male fertility and other aspects of male reproductive function.
Introduction
With the completion of various mammalian and other vertebrate genome projects, we now have a good overview of the evolution of the peptide hormone relaxin and its relatives within these genomes, as well as of their cognate receptors. The objective knowledge provided by this information allows a critical reappraisal of much of the experimental literature on the importance of relaxin-like peptides within the male reproductive system. Why this is needed is evident from the wide range of articles, both historical and actual, which span opinions from relaxin being of no relevance whatsoever in the context of male reproduction, to it being a major hormonal influence and essential component of male fertility.
Structure and synthesis of relaxin-family peptides
The relaxin-like peptides belong to the larger family of insulin-like peptides characterized by a common three-domain structure (Fig. 1 ). All are made by translation of a single pre-pro-polypeptide from a single gene, whereby the C (connecting) peptide is essentially a linker between the B-domain located at the N-terminus immediately following the signal peptide and the C-terminally located A-domain (Fig. 1) . The B-domain is largely, though not exclusively, responsible for primary interaction with the receptors, whereas the A-chain is essential for holding the B-chain in the correct three-dimensional conformation for receptor interaction and activation . For most members of the family, it is largely unclear whether or not the C-peptide is excised completely in vivo, although most sequences do indicate flanking basic residues suggestive of furin or convertase cleavage sites. In only a few studies has the molecular form of the circulating peptide been analysed. For the ovarian relaxin in humans (H2 relaxin, RLN2) and rats (RLN1), chromatography suggests that the circulating hormone is secreted as both the cleaved 6000 Da A-B heterodimer and the uncleaved (or partially cleaved) A -B -C propeptide (Sherwood et al., 1984; O'Byrne et al., 1989; Eddie and Tregear, 1995; Layden and Tregear, 1996) . For INSL3, chromatography of the bovine peptide from the testis also implicates an 6000 Da heterodimer (Bullesbach and Schwabe, 2002) . However, the chromatography indicates a substantial amount of specific immunoreactivity in the exclusion volumes of the columns, implying the presence of larger immunoreactive forms of the peptides which could be either precursors or protein-bound moieties. Most specific antibodies raised against the heterodimeric peptides cannot distinguish these from the longer C-peptide containing precursor forms. This probably is not physiologically important since several groups have shown that the A-B-C precursor molecules are just as bioactive at the receptors as the cleaved A -B heterodimers (Vu et al., 1993; Zarreh-Hoshyari-Khah et al., 2001) . This is different from the situation among the insulin or IGF members of this peptide superfamily, where for insulin the precursor must be cleaved to the A -B heterodimer for it to become biologically active, and for both IGF1 and IGF2 the C-domain is short and never cleaved. For all other members of the relaxin-like peptide subfamily, we still have no information as to the molecular nature of the secreted and/or bioactive forms that naturally occur in vivo. We do know that chemically synthesized A-B heterodimers for most peptides appear to be fully bioactive, and that recombinantly made pro-forms are often also bioactive.
Like all other secreted peptide hormones, relaxin is synthesized first as a pre-pro-peptide with the N-terminal pre-or signal sequence being co-translationally cleaved as the nascent polypeptide is sequestered into the lumen of the endoplasmic reticulum of the hormoneproducing cells. From here, the pro-hormone (A -B -C propeptide) is probably transported via the Golgi apparatus to secretory granules (electron dense), which would then be released upon specific stimulation. There is definite evidence of this for ovarian relaxin; whether this is true for all tissues and all related peptides is unknown, particularly where evidence points to a constitutive mode of expression, as for INSL3 (Balvers et al., 1998; Sadeghian et al., 2005) . To produce the A-B heterodimer found in the circulation, furin-like convertases need to access the specific lysine-and arginine-rich cleavage sites flanking the C-domain (Marriott et al., 1992) . This is likely to occur within the secretory granules at acidic pH, though again this has only been shown for relaxin (Marriott et al., 1992) . This discussion is important because when extracting tissues and subjecting them to western blot analysis, the major immunoreactive component is most likely to be the pro-form, missing the N-terminal signal peptide. The pre-pro-form of all peptide precursors is highly transitory and rarely if ever seen. Also the A-B cleaved heterodimer is only likely to be present in tissues where there is high hormone turnover and secretion. For hormones like relaxin and INSL3 where we suspect that also substantial quantities of the pro-form are being secreted together with the heterodimer, then the most likely immunoreactive species inside cells will be the A -B -C pro-form (Fig. 1) .
Evolution of the relaxin family peptides
Summarizing recent reviews on the evolution of the relaxin-like peptide family (Wilkinson et al., 2005; Wilkinson and Bathgate, 2007; Park et al., 2008) , insulin is considered to be the stereotypic ancestor, and gave rise to a series of insulin-like peptides in all animals of which insulin, IGF1 and IGF2 are the vertebrate representatives. Early in the deuterostome lineage, the peptide relaxin 3 (RLN3) evolved and became the ancestor for all relaxin-like peptides. RLN3 radiated within teleost fish to give several related nonsynonymous genes about which we still know functionally very little. Importantly, RLN3 within other vertebrates became linked with reproductive function. The well-described 'relaxin' (Steinetz et al., 1998) isolated as peptides from the ovaries and testes of elasmobranchs (sharks and rays) can now be recognized as RLN3, as is also, in all probability, the 'relaxin' identified in the gonads of chicken and frogs (Brackett et al., 1997; De Rienzo et al., 2001) .
Just prior to mammalian emergence, RLN3 underwent successive duplications (Fig. 2) , first giving rise to a peptide which was the ancestor of both ovarian relaxin (RLN: note that the abbreviation RLN will be used to signify the H2 relaxin gene product in humans and anthropoids and the homologous RLN1 gene product in rodents and other mammalian species; where the H1 relaxin gene of humans and anthropoids is referred to, it will be called H1-RLN) and INSL3 (see Table I for a full list of abbreviations and aliases). This retained the ancestral gonadal expression pattern, as well as a close genetic linkage to the sex-determining DMRT1 region of the sex chromosomes in birds, monotremes and eutherian mammals (Ivell and Grutzner, 2009 ). Later, RLN3 duplicated again to give rise to INSL5. Both RLN3 and INSL5 maintain non-gonadal expression patterns in modern mammals predominantly, though not exclusively, with RLN3 mainly being a neurohormone of the brain, and INSL5 a hormone of the gut. Subsequently, the common ancestor of RLN and INSL3 duplicated again to give rise to the mainly ovarian (RLN) and testicular (INSL3) hormones with which we are familiar. The former retained its location in the DMRT1 syntenic region, whereas INSL3 moved to another chromosomal location. During mammalian and especially primate evolution, we witness more gene duplications and divergence, with first INSL6 evolving and retaining predominantly gonadal expression, then INSL4 and human H1-RLN emerging in higher primates, with mostly placental expression. All four genes (RLN, H1-RLN, INSL4, INSL6) also retained their syntenic location within the DMRT1 region (Ivell and Grutzner, 2009) .
Within the male reproductive system, therefore, we can expect to find expression of different members of the relaxin family of peptide hormones. INSL3 has been extensively reviewed elsewhere (Ivell and Bathgate, 2007; Ivell and Anand-Ivell, 2009 ) and is expressed almost exclusively by the interstitial Leydig cells of the testis Balvers et al., 1998) and at a much lower level also by the prostate (Klonisch et al., 2005) . INSL6 has been reported within meiotic and post-meiotic male germ cells (Lok et al., 2000; BurnickaTurek et al., 2009) , and the recent knockout mouse study implies a role in protecting germ cells from apoptotic insults (Burnicka-Turek et al., 2009 Relaxins in the male the relaxin family of hormones have proved negative (Wilkinson et al., 2005; Wilkinson and Bathgate, 2007) . The INSL5 gene is expressed only at very low levels in the testis (Conklin et al., 1999) , and is generally negative in all microarray data for testes and other tissues of the male tract in the GEO database.
Receptors for relaxin and related peptides
When in 2002 Teddy Hsu identified and cloned the receptor for ovarian relaxin as the G-protein-coupled receptor (GPCR) LGR7 (Hsu et al., 2002; now RXFP1) , relaxin physiology could finally be exposed to full molecular analyses of both hormone and receptor systems. The evolution of the insulin-relaxin family of peptide hormones was accompanied also by successive shifts in the receptors being used . Unlike insulin and the IGFs, which use tyrosine kinase receptors, when RLN3 evolved it adopted the exclusive use of a class A GPCR with a short extracellular domain, now referred to as RXFP3 (previously GPR135; Table I ). When RLN3 duplicated to give rise to INSL5, also the receptor duplicated to become RXFP4 (previously GPR142; Table I ), which is structurally closely related to RXFP3. Both GPCRs predominantly couple to PI3-kinase and Ca 2+ intracellular signalling pathways. With the later evolution of ovarian relaxin and INSL3 just prior to mammalian emergence, another class of GPCRs was adopted, the leucine-rich repeatcontaining LGR members LGR7 (now RXFP1) and LGR8 (now RXFP2), respectively. These receptors have long and complex extracellular domains, and belong to an ancient class of molecules also including the receptors for the glycoprotein hormones TSH, FSH and LH (Hsu et al., 2003) . In contrast to the receptors for RLN3 and INSL5, these receptors mainly, though not exclusively, make use of Gs coupling to adenylyl cyclase to generate the second messenger cAMP (Hsu et al., 2003; Halls et al., 2007; Anand-Ivell et al., 2007) . Detailed pharmacological studies Halls et al., 2007) show that although INSL3 and RXFP2 in vivo represent an exclusive hormone-receptor pair (Bogatcheva et al., 2003) , with human RLN only able to activate RXFP2 at high concentrations, RXFP1 can be activated by both human RLN and H1-RLN, as well as by RLN3 (Fig. 3) . Similarly, RXFP3 can be activated by both RLN3 and RLN, and to a lesser extent by INSL5. RXFP4 is activated mainly by INSL5, though can also cross-react with RLN3, but not with RLN, nor, of course, with INSL3 (Fig. 3) . These relationships need to be understood if we are to comprehend possible effects of relaxin-like peptides in the male reproductive tract. Although for the circulating hormones we can probably disregard the promiscuous activation of other receptors at high ligand concentration, this may not be true for autocrine/paracrine relationships in the vicinity of sites of local synthesis, where local hormone concentrations can be very high. It is also important to recognize that although some circulating hormone concentrations can be quite low, most of these receptors can be activated, although briefly, by concentrations of ligand as low as 1-10 pM (6-60 pg/ml) of their specific ligand, or even by concentrations in the subpicomolar range (Halls and Cooper, 2010) . Also, higher concentrations can lead to long-term receptor desensitization and hence loss of hormone effect.
Expression of relaxin-like peptides in the testis
The expression of INSL3 has been covered extensively elsewhere (Agoulnik, 2007; Ivell and Bathgate, 2007; Ivell and Anand-Ivell, 2009) ; here discussion will be mostly limited to the other members of the relaxin-like peptide family. Although expression of an mRNA gene transcript is a precondition for local synthesis of the peptide, it is not a substitute for assessing expression at the peptide level. Both RLN and INSL3 genes can also be expressed as non-functional splice variants (Gunnersen et al., 1996; Zarreh-Hoshyari-Khah et al., 1999; Spiess et al., 1999) , which could lead to positive mRNA signals by in situ or northern RNA hybridization, on microarrays, or by some RT-PCR reactions. Thus expression of some testicular mRNAs does not necessarily lead to translation into the encoded peptide (Ivell, 1992) , making independent confirmation of expression at transcript and peptide levels essential.
Inspection of unbiased microarray results within the GEO database indicates that, unlike INSL3 and INSL6, INSL5, RLN and RLN3 are mostly undetectable in the testes of mice, rats and humans, or at the level of detection. For RLN3, we have confirmed this by RT -PCR (Fig. 4) , implying weak transcript expression in a somatic cell component, probably Leydig cells. This supports the study at the peptide level by Silvertown et al. (2010) using a monkey model (see below). In contrast, targeted studies have indicated specific low-level INSL5 mRNA expression in human testes by northern blot (Conklin et al., 1999) , and RLN mRNA expression in the Leydig cell fraction (though not in the Sertoli cell fraction) of the boar testis by RT -PCR (Kohsaka et al., 2009) , as well as in whole boar testis (Lobb et al., 1995) ; there appears to be low-level RLN mRNA expression by quantitative RT -PCR in the Sertoli cell fraction of the rat testis (Cardoso et al., 2010) . In this last study, it was suggested that RLN mRNA expression was 15-fold less in the testis than in the prostate (see below), confirming the earlier study by Gunnersen et al. (1995) .
INSL6 represents an interesting departure from what one might expect from a molecule which appears to have evolved from a common ancestor to RLN, INSL3 and RLN3. Namely, unlike these, it appears to be expressed at a relatively high level uniquely in the male germ cells, both in pre-and post-meiotic stages (Burnicka-Turek et al., 2009) .
At the level of peptide expression, RLN3 has been identified immunohistochemically using validated antibodies in the interstitial region (presumably Leydig cells) of both rhesus and human testis (Silvertown et al., 2010) . In this study, the seminiferous tubules were negative. This result is in good accord with studies at the RNA level of frog relaxin (presumed RLN3; De Rienzo et al., 2001 . Immunohistochemistry using the R19 antibody against porcine RLN has also been used to identify expression of RLN peptide in the interstitial cells of the boar testis (Kohsaka et al., 2009) , essentially confirming earlier work by Dubois and Dacheux (1978) , who additionally found somewhat weaker staining in the Sertoli cells. In contrast, Cardoso et al. (2010) claim expression of RLN immunoreactivity only in the Sertoli cells of the rat and not in the interstitial compartment. This is supported by western blot of whole-testis extracts using another antibody. Here it is to be noted that, unlike the immunohistochemistry, which appears to use an antibody raised against the rat RLN precursor, the western blot made use of anti-human RLN antibody raised using a peptide with only 50% homology to the rat sequence; furthermore, the size of the immunoreactive product tallied not with the expected size of the pro-form, but rather with that of the pre-pro-polypeptide, which as indicated above is a highly unlikely outcome. The situation in the boar testis also needs comment. Many antibodies raised against relaxin, of which the R6 antibody is possibly the best characterized (O'Byrne and Steinetz, 1976) , recognize the receptor-binding site on the B-domain of relaxin as highly immunogenic. Although the primary amino acid sequences of RLN and RLN3 may differ somewhat, the fact that these two peptides can share specific binding to the same receptors (Fig. 3) would suggest that antibodies recognizing the receptor-binding domain of RLN might cross-react with that of RLN3, which presumably adopts a similar conformation and charge distribution.
In summary, therefore, except for INSL3 and INSL6, relaxin-like peptides in the testis in modern mammals are variably expressed, though all at a low level. Mixed evidence suggests expression either in the interstitial Leydig cells or in Sertoli cells, possibly depending on species. Compared with expression levels in the prostate gland (see below), testicular expression is low and unlikely to influence all but very local systems within the gonad.
Expression of relaxin family receptors in the testis
Potential functionality for the relaxin-like peptides can be assessed by looking at transcript expression for their receptors. The sequences for Figure 4 Semi-quantitative reverse transcription PCR to determine transcript expression for RLN3, the receptors RXFP1, RXFP3 and RXFP4, and as a loading control the small ribosomal protein S27a. Target cDNA was prepared from mouse tissues and cell lines as indicated exactly according to Anand-Ivell et al. (2006) the genes for RXFP1-RXFP4 are all known, and hence PCR or microarray strategies can be devised. It should be noted that the gene for RXFP4, the specific receptor for INSL5, is absent in rats (but not in mice). Nevertheless, caveats are required, the most important of which relates to the possibility, particularly for RXFP1 and RXFP2, that these genes are transcribed in multiple splice variants, most of which lead to non-functional gene products. If expressed as protein, some of the splice variant receptors can also act in a dominantnegative fashion inhibiting the function of correctly expressed receptors (Scott et al., 2006; Kern et al., 2008) . To account for such possibilities, we and others have developed a matrix of PCR primers covering all 18 exons of both RXFP1 and RXFP2 receptors from rodents and humans (Muda et al., 2005; Anand-Ivell et al., 2006; Heng et al., 2008) , which allows a detailed analysis of receptor transcript expression in a particular cell or tissue. RXFP2 is expressed by both Leydig cells and post-meiotic germ cells (Anand-Ivell et al., 2006; Feng et al., 2007a; Filonzi et al., 2007) . This receptor is activated almost exclusively by INSL3 and only at high concentrations of RLN, which do not exist within the testis. The location of these receptors within the germ cell compartment, confirmed by immunohistochemistry also for the human (Anand- Ivell et al., 2006) , is fully in agreement with the role of INSL3 in the adult testis to act as a survival or anti-apoptosis factor vis-à-vis germ cells. Moreover, we have recently shown that although INSL3 is made within the interstitial compartment, considerable amounts also cross the blood -testis barrier to enter the seminal compartment . RXFP1 transcript expression has been studied using simple RT -PCR for the 3 ′ exons in the boar testis (Kohsaka et al., 2009) and shown to be expressed equally in both Leydig and Sertoli cell fractions. RXFP1 transcripts are also detectable in the rhesus monkey testis (Silvertown et al., 2010) and in the rat testis (Filonzi et al., 2007) . Cellular localization by immunohistochemistry in the rat suggests expression in post-meiotic germ cells, on Sertoli cells and in peritubular cells (Filonzi et al., 2007; Avellar et al., 2009) , although it should be noted that the antibodies used were raised against a human peptide with 7 mismatches in 22 amino acids (for RXFP1). The implication from the latter study is that RLN receptors may be present on mature spermatozoa, which would have considerable significance for the interpretation of some of the results concerning relaxin effects on sperm (see later). Some of the most convincing results regarding RXFP1 expression come from knockout mouse studies where, in addition to removing part of the RXFP1 gene, a b-galactosidase gene has been inserted, thereby being driven from the specific RXFP1 promoter (Krajnc-Franken et al., 2004) . In these mice, RXFP1 expression is shown in sporadic post-meiotic germ cells and weakly in Leydig cells. Our own studies using a simple RT -PCR approach in various testicular components and cell-lines from mice ( Fig. 4 ; previously unpublished results) would agree with this and support RXFP1 expression in most cell types of the mouse testis. However, employing a panel of well-validated anti-human RXFP1 antibodies (Ivell et al., 2003b) , we have so far been unable to detect any specific immunohistochemical signals in the human testis (unpublished). RXFP4, but not RXFP3, gene transcripts can be detected in the rhesus monkey testis by RT -PCR (Silvertown et al., 2010) . Otherwise, there is very little information about either of these receptors in the testis. Our own preliminary studies using semi-quantitative RT -PCR suggest the expression of both RXFP3 and RXFP4 gene transcripts in the mouse testis (Fig. 4) , with relative levels in different compartments strongly implying a somatic cell expression pattern in both Leydig and Sertoli cells. Note that in the rat, the RXFP4 gene is completely missing. A summarized description of sites of expression for both peptides and receptors is given in Table II .
Physiology of relaxin in the testis
INSL5 knockout mice appear to be completely without phenotype, including consideration of male fertility and testis parameters (http:// jaxmice.jax.org/strain/005819.html). Similarly, RLN3 knockout mice for which preliminary phenotypic data are available (Sutton et al., 2009) 2001; Gorlov et al., 2002) and, provided testes are surgically descended shortly after birth, appear to have no other fertility-or testisrelated phenotype (Nef and Parada, 1999; Overbeek et al., 2001; Nguyen et al., 2002) . If the cryptorchidism is allowed to persist, then there will be heat effects on spermatogenesis, leading to germ cell apoptosis and dysgenesis of the spermatogenic epithelium (Nguyen et al., 2002) . Interestingly, there does appear to be an effect of INSL3 on germ cells in the adult animal, with INSL3 peptide being reported to protect against a pro-apoptotic insult (Kawamura et al., 2004) , and an INSL3 antagonist being able to induce a loss of testis weight ( The situation for RLN in the rodent testis is controversial. Both the RLN knockout mouse and at least one report of RXFP1 knockout mice indicate very similar phenotypes (Zhao et al., 1999; Samuel et al., 2003; Krajnc-Franken et al., 2004) , supporting the notion that, although pharmacologically this hormone-receptor pair is able to act promiscuously with other ligands and receptors, physiologically this does not occur with high incidence. The issue here is that both genotypes indicated a male reproductive phenotype in their first generations, and that this was largely lost in subsequent generations (Krajnc-Franken et al., 2004; Ganesan et al., 2009) . A second independent production of RXFP1 knockout mice reported a complete absence of a male phenotype, with homozygous mutant males being indistinguishable from wild types and with no impairment of fertility (Kamat et al., 2004) . The early phenotype of the RLN knockout mouse has been well characterized by Samuel et al. (2003 Samuel et al. ( , 2007 . These mice were generated on a 129sv genetic background and largely from the F2 and F3 generations. Testes and other organs of the male tract were collectively reduced in weight, due to dysgenesis of the seminiferous tubules, many of which indicated a loss of germ cells. In addition, testes exhibited marked fibrosis, particularly in older animals, assessed both by Masson trichrome staining and by increased hydroxyproline content. This effect could be reversed by chronic relaxin infusion (Samuel et al., 2007) . Significantly, the incidence of apoptotic cells in the seminiferous compartment was elevated as measured by Bax and caspase-9 staining (Samuel et al., 2003) . For the Dutch RXFP1 knockout mice, results were very similar (Krajnc-Franken et al., 2004) , with testis weights being substantially reduced, largely due to marked agenesis of the seminiferous epithelium, and with a high level of TUNEL staining of germ cells indicating apoptosis. In both knockouts, the authors report a lack of mature sperm in some individuals and initially at least a reduced male fertility. For the Dutch RXFP1 knockout mice, fertility rates were improved already by the F2 and F3 generations (Krajnc-Franken et al., 2004) . We have recently reassessed the testicular phenotype of the RLN knockout mice from the same colony as used 8 years previously by Samuel and co-workers (2003) , still on the 129sv background, and find little evidence of any major fertility impairment in the homozygote mutant animals ( Fig. 5; previously unpublished results) . Particularly at 12 months of age, where there is anyway increased evidence of fibrosis, we see non-significant trends towards a thicker tunica albuginea in the knockout mice and a decreased expression of the postmeiotic germ cell marker ELP ( Fig. 5A and B) . However, there is evidence for a significantly increased fibrosis (P , 0.05) between wildtype and rln 2/2 mice when the tunica albuginea thickness is averaged for each age and the individual data are expressed as percentage variation from the means and collated for all age groups. For specific gene expression measured by real-time RT -PCR, there are some significant differences between RLN knockout mice and their wildtype siblings, but only at 12 months (Fig. 5C ). This lack of major effect is comparable with what has recently been reported by another group using an RLN knockout genotype on a C57BL/6 background (Ganesan et al., 2009) . How should we interpret these results? There is a tendency to accept as a 'real phenotype' only traits which persist unchanged over many generations and on different genetic backgrounds. The assumption here for the rln 2/2 mice is that any apparent phenotype was 'caused by genetic or epigenetic alterations in other parts of the mouse genome and were, in fact, not related to the targeted genes' (Ganesan et al., 2009) . Male fertility in the mouse is subject to a number of modifier genes, making it genetically relatively intractable. Some traits are only apparent in a variable genetic background and are lost in an inbred strain (Ivell and Grutzner, 2009) . By definition, most knockout mouse colonies become relatively inbred quite quickly, so that the observed partial penetrance and loss of a male fertility phenotype should not be unexpected. A very similar phenomenon and phenotype was recently observed for the INSL6 knockout mouse (Burnicka-Turek et al., 2009) . In contrast to the citation above, a transient phenotype such as that observed in the RXFP1 and RLN knockout mice should be taken as evidence of a genuine physiology, but one which because of redundancy, genetic modifiers and possibly transgenerational epigenetic modification can be masked by inbreeding. The common early phenotype shared by these two mutations is sufficiently complex and predictable from known relaxin physiology that it is unlikely to be the serendipitous result of unspecific genetic and epigenetic changes unrelated to the target genes. It is significant that this phenomenon of transgenerational masking is often observed for genes involved in male and female fertility, where there are likely to be strong selection pressures favouring such modifications and epigenetic effects. 
×100 magnification). (B)
Quantification of various testis parameters as indicated from adult male RLN knockout and wildtype sibling mice. ELP immunostaining is a highly specific measure of post-meiotic round and elongated spermatids (Pusch et al., 2000) . Whereas the age-dependent changes in the thickness of the tunica albuginea are statistically significant (P , 0.05), with the small number of animals studied per group (N ¼ 3) there is no significant difference between wildtype and knockout mice for any parameter, although a trend towards increasing fibrosis in the rln 2/2 mouse is evident and does become significant (P , 0.05) when tunica albuginea thickness data from all ages are collated as percentage variations from the agedependent means (not shown). (C) Real-time RT-PCR carried out exactly as described elsewhere (Anand-Ivell et al., 2006) on RNA extracted from RLN knockout and wildtype sibling testis of 3, 6 and 12 months of age to measure relative transcript levels for metalloproteinases 2 (MMP2)
To clarify the issue of relaxin physiology in the male, studies are required which would allow transient or conditional expression of a relaxin antagonist within the testis of different species over a period of sufficient time to allow the generation of a phenotype such as fibrosis or spermatogenic dysgenesis.
Relaxin-like peptides have been applied to different testicular cell types in culture with variable results. INSL3 has been shown to act via a Gi-linked system to affect meiosis in male germ cells (Kawamura et al., 2004) , though has little apparent effect on normal mouse and rat Leydig cells which also express RXFP2 receptors (unpublished). Relaxin has been shown to induce cell proliferation in primary cultures of immature rat Sertoli cells, apparently countering effects of FSH (Cardoso et al., 2010) , though is without effect on steroidogenesis, cAMP production or INSL3 synthesis in the mouse MA10 Leydig cell line (unpublished) . No information is available on the other peptides about testicular cell responses.
Physiology and regulation of relaxin in the prostate and male accessory glands Relaxin-like peptides and/or their receptors have been identified, depending on the species, in all parts of the male reproductive tract including the epididymis, vas deferens, seminal vesicles and prostate gland. Both RLN and RXFP1 have been identified as transcripts and immunohistochemical signals expressed within the vas deferens epithelium and tunica (Avellar et al., 2009; Cardoso et al., 2010) . Furthermore, RLN has been shown to affect cultured adult vas deferens by altering the gene expression of CFTR, MOS2 and MMP7 (Cardoso et al., 2010) , though not of MMP2 and MMP9. The actual levels of RLN transcripts in the vas deferens, however, are extremely low, substantially less than in the prostate (see below).
For the epididymis, both RXFP1 and RXFP2 gene transcripts have been identified in epithelial cells (Anand-Ivell et al., 2006; Feng et al., 2007a; Filonzi et al., 2007) . There is very little information on the expression of the relaxin-like peptides in the epididymis, except that in several studies, e.g. on RLN3 in monkeys (Silvertown et al., 2010) or RLN in humans (Yki-Jarvinen et al., 1983) , this organ is considered to be negative. It should be noted that INSL3 of testicular origin is present in rat epididymal fluid in quite substantial concentrations ( 10 ng/ml; Anand-Ivell et al., 2009) and presumably acts as a component of the lumicrine system (Hinton et al., 1998) . There is no information about other relaxin-like peptides in the epididymis, nor about the receptors RXFP3 and RXFP4.
In the context of relaxin physiology, by far the best characterized organ of the male tract is the prostate gland. This was recognized early on as the major source of relaxin in the male of humans, primates and rats (Yki-Jarvinen et al., 1983; Ivell et al., 1989; Bogic et al., 1995; Gunnersen et al., 1995; Einspanier et al., 1997) , and it shows up prominently in microarray studies from rodents and humans. Interestingly, in the human prostate at the mRNA level there appears to be expression also of H1 relaxin gene transcripts (Hansell et al., 1991; GEO database) . Immunohistochemically, relaxin is identified mostly in the glandular epithelial cells of the prostate (Yki-Jarvinen et al., 1983; Sokol et al., 1989) , from where it presumably is also exported into seminal fluid. It is also made by similar cells in the human seminal vesicles (Yki-Jarvinen et al., 1983) , and in pigs the seminal vesicles appear to generate more relaxin than the prostate gland (Kohsaka et al., 1992) . In the rodent prostate at the immunohistochemical level, relaxin appears to be difficult to detect (Anderson et al., 1986) .
Studies of the various mouse strains, where either relaxin-related peptides or their receptors have been ablated, indicate that only for RLN does there appear to be any phenotypic consequence of the gene ablation (Samuel et al., 2003) , notably in an increased fibrosis of the prostate with up to 40% higher levels of hydroxyproline, indicating substantially increased collagen content. Subsequent studies either of RXFP1 knockout mice (Kamat et al., 2004; Krajnc-Franken et al., 2004) or of RLN knockout mice which have been crossed into a C57BL/6J background (Ganesan et al., 2009) failed to identify any phenotypic consequences within the prostate gland. This may represent another example, as above, where inbreeding in some as yet unknown way is able to suppress the negative effects of a RLN mutation, or it may be that the prostate gland indeed is independent of relaxin effects, at least in mice.
Why caution is warranted here is that there is now very clear evidence from the human that RLN and RXFP1 are important factors in the growth and development of prostate carcinoma. Earlier studies had identified local relaxin gene expression by the LNCaP human prostate carcinoma cell line (Gunnersen et al., 1995; Garibay-Yupas et al., 2000; Figueiredo et al., 2005) , where both H1 and H2 relaxin genes are expressed (Garibay-Yupas et al., 2000) . In prostate carcinoma tissue samples, relaxin immunoreactivity appears to increase with tumour development, especially when tumours attained androgen independence or in bone metastases (Thompson et al., 2006; Feng et al., 2007b) . The ability of androgens to inhibit relaxin expression was also shown in both LNCaP cells in culture and in LNCaP xenografts (Thompson et al., 2006) . Conversely, relaxin has been shown to engage in signalling cross-talk with the androgen receptor in LNCaP cells, such that even in the absence of androgen, this and 9 (MMP9), and for the Leydig cell products INSL3 (Pusch et al., 1996) and 17b-HSD type 10 (17bHSD10; Ivell et al., 2003a nuclear receptor becomes activated (Vinall et al., 2006; Liu et al., 2008) . Thus relaxin is not only a marker for prostate cancer progression, but itself exacerbates tumour growth and differentiation. This has been shown also directly in LNCaP and PC3 xenograft studies (Silvertown et al., 2006; Feng et al., 2007b) , whereby RLN also caused increased tumour angiogenesis (Silvertown et al., 2006) . Importantly, a peptide analogue of RLN with antagonist properties appeared to inhibit tumour growth in this xenograft model (Silvertown et al., 2007) . This role of RLN in promoting prostate tumour growth is very similar to what has been reported also for breast cancer (Binder et al., 2002) , where it has been shown that RLN promotes collagen turnover through the expression of the metalloproteinases MMP2 and MMP9, and accelerates cell movement in a transmigration assay (Binder et al., 2002) . All of these properties support a role for relaxin in the growth, differentiation, metastasis formation and angiogenesis of epithelioid prostate cancer.
Finally, it should be noted that most of these findings for RLN are also paralleled by studies on INSL3 and its cognate receptor RXFP2 (Klonisch et al., 2005) . Both the ligand and its receptor appear to be expressed in epithelial-type cells of normal prostate, benign prostatic hyperplasia and prostate carcinoma, implying a local autocrine-paracrine system. Unlike RLN and its receptor, RXFP1, INSL3 and its receptor are absent from LNCaP cells, though present in PC3 and the hPCP cell lines (Klonisch et al., 2005) . Here INSL3 had no effect on cell growth or metabolism, though did increase cell motility. As mentioned above, there is no information for any of the other relaxin-like peptides or receptors in the context of prostate hyperplasia or cancer, and the GEO database is not informative here.
Role of relaxin in seminal fluid
Seminal fluid from various species, including humans, has been analysed for relaxin immunoreactivity for several decades, and appears to have a higher concentration of relaxin-like molecules than circulating blood. Depending on the anti-relaxin antibodies used, different relaxin concentrations have been determined. Using the R6 antiporcine relaxin antibody, the relaxin concentration in human seminal plasma is recorded as being as high as 50 ng/ml (Colon et al., 1994) or as low as 7.5 ng/ml (Essig et al., 1982) . In an interesting comparative study again using the R6 antibody, Kohsaka et al. (2003) indicated seminal relaxin concentrations of 41.9 ng/ml in bulls, 17.4 ng/ml in humans, 13.1 ng/ml in rams, 2.4 ng/ml in boars and 1.0 ng/ml in goats. These figures for human seminal relaxin are quite different from those reported in other studies using other also wellcharacterized and validated antibodies ( 1.6 ng/ml, Armbruster et al., 2001; 1.5 ng/ml, Schieferstein et al., 1993) . There is an order of magnitude discrepancy here which requires explanation. Also the results for the boar are considerably higher than in other studies (e.g. Anderson et al., 1995; 0.5 -1 .0 ng/ml). The answer lies in the data provided by Kohsaka et al. (2003) : in bulls, rams and goats whatever is being measured cannot possibly be RLN, since the RLN gene, which is homologous to the gene in boars and humans, has been deleted from the genome in bovid ruminants (Roche et al., 1993 ; http://bovinegenome.org). The reason that the highly specific R6 antibody is able to cross species boundaries in its applications is because the antigenic epitope appears to be localized to the highly conserved receptor-binding domain which is likely to be shared by most RXFP1-binding ligands, and possibly other molecules. It would appear that at least in seminal fluid, it is cross-reacting with some molecule which is not relaxin. Why this is important is that the higher figures are being used as evidence of normal physiological concentrations of relaxin in seminal fluid for applications of relaxin on in vitro sperm functionality. An amount of 10 or 100 ng/ml relaxin (equivalent to 1.6-16.6 nM) is not a physiological concentration of relaxin in the male; rather what sperm will be seeing are concentrations probably more in the range of 0.1 -0.3 nM. Caution is required, however, until more studies using different validated antibodies can confirm the true concentration of relaxin in seminal plasma.
Although all available evidence still suggests that most seminal relaxin in the ejaculate is likely to be derived from the prostate gland or from seminal vesicles, we must unfortunately discount the compelling evidence from the older studies using split ejaculates (De Cooman et al., 1983) or in men with congenital absence of the vas deferens (Essig et al., 1982; De Cooman et al., 1983) since these studies relied on the R6 antibody (see above).
Because of the apparently high relaxin concentrations in seminal fluid, there have been numerous studies attempting to show effects of relaxin on sperm functional parameters. The older studies have been comprehensively reviewed by Weiss (1989) , who came to the conclusion that 'relaxin appears to affect human sperm motility and sperm-fertilizing capability in the zona-free hamster egg-sperm penetration test, but only in suboptimal samples'. More recent studies have not really changed this viewpoint. It should be noted that where significant effects on sperm parameters are seen (e.g. Han et al., 2006; Miah et al., 2006) , this is usually at concentrations of relaxin in excess of 20 ng/ml, which we should now realize is probably a supraphysiological concentration. The discussion about sperm responses to relaxin has recently been rekindled with the putative identification of RXFP1 and/or RXFP2 receptors (or gene transcripts) in post-meiotic germ cells (Kawamura et al., 2004; Anand-Ivell et al., 2006; Filonzi et al., 2007) , and possibly also on free spermatozoa (Gianesello et al., 2009) , tentatively confirming the earlier high-affinity relaxin-binding properties of human sperm (Carrell et al., 1995) . Although currently we cannot confirm or refute an effect of relaxin on sperm functions, our new knowledge of relaxin action at its specific GPCR receptors strongly implies that, if such effects are specific, we should see them at concentrations of relaxin in the low nanomolar range. The fact that, in many studies, in excess of 10, or even 100 nM relaxin is required to achieve an effect is more likely pointing to another less specific mechanism of action. For example, because of the six cysteine residues in the relaxin molecule, it also has potential anti-oxidative properties and would thus act as a good protectant against the known effects of ROS on sperm function. This can be tested simply by comparing native relaxin with relaxin that has been heat-denatured and is thereby unable to interact with specific receptors (Dschietzig et al., 2004) .
Finally, the function of seminal fluid does not end at ejaculation. Seminal fluid has important properties also within the female tract and has been shown to improve implantation rates in pigs and rodents (Robertson, 2007; Schuberth et al., 2008) , where it is presumed to act indirectly on immune cells to desensitize these in preparation for genetically foreign sperm and foreign embryos. Indeed, natural intercourse has been shown to improve IVF success also in humans (Tremellen et al., 2000) . It is well-known that relaxin can act on the cervix to induce tissue softening in a wide range of species (Parry and Vodstrcil, 2007; Simon and Einspanier, 2009; Yao et al., 2010) . We recently carried out experiments in mice, introducing relaxin directly into the uterine lumen at oestrus and showed a significantly increased gene expression and secretion of some proinflammatory cytokines (unpublished). Although preliminary, such experiments emphasize a possible role for seminal relaxin also within the female reproductive tract in the context of immune desensitization.
Except for INSL3 in the rat, which is present at concentrations of 10 ng/ml in epididymal fluid (Anand-Ivell et al., 2009), we have no information about the concentrations of any of the other relaxin-like peptides in either seminal fluid or other fluid compartments of the male tract for any species. Similarly, no other relaxin-like peptide apart from RLN has been studied in the context of sperm physiology.
Concluding remarks
In the last 10 years, we have seen relaxin physiology in the male move from being a relatively simple system, with few components, a restricted and dubious functionality associated with sperm motility, and several black boxes, to a post-genomic complex system involving multiple potential receptors, a larger number of potential ligands and important new functions linked to spermatogenesis, prostate cancer, fibrosis, angiogenesis and immune preparation of the female tract. The increased knowledge is accompanied also by a need for new paradigms by which to understand how such complex and potentially redundant systems function, for example, in the context of the disappearing knockout phenotypes. The increased knowledge also has demanded a re-examination of much of the older data, which as we have seen, is now open to multiple interpretations. At a time when relaxin is being clinically trialled for its life-saving benefits in cardiovascular disease (Dschietzig et al., 2009) , and RLN3 is being explored as a new neurological parameter (Callender and Bathgate, 2010) , it is appropriate to look again at relaxin in male physiology. The relaxin family of peptides has evolved closely alongside the key genes involved in sex determination and gender definition (Ivell and Grutzner, 2009) . It comprises many new members of what are collectively coined 'neohormones' , whose evolutionary and pharmaceutical advantages lie in representing 'add-on' modifying functions which have catalysed the success of modern mammals. This property, however, demands also new experimental paradigms which allow the exploration of redundant and pleiotropic systems, not limited by classical reductionism. In view of the growing clinical importance from a causative, diagnostic and therapeutic perspective of relaxin family peptides in prostate pathology, and by analogy probably also in regard to male fertility, there is a substantial need now for properly controlled and specific studies on the physiology of this important new family of hormonal factors in all aspects of male reproductive function.
